News | Atrial Fibrillation | July 03, 2017

Medtronic Reactive ATP Therapy Slows Progression of Atrial Fibrillation in Real-World Population

Data presented as late breaking clinical trial at EUROPACE 2017

Medtronic Reactive ATP Therapy Slows Progression of Atrial Fibrillation in Real-World Population

July 3, 2017 — Medtronic recently announced that its Reactive ATP therapy slows the progression of atrial fibrillation (AF) in patients with implanted cardiac devices. A robust, real-world analysis of nearly 8,800 patients was presented as a late breaking clinical trial at EHRA EUROPACE-CARDIOSTIM 2017, June 18-21 in Vienna, Austria.

An unusually fast or quivering rhythm in the heart's upper chambers (atria), AF is a progressive disease that afflicts more than 33 million people worldwide. Common among patients with cardiac devices, AF impairs quality of life and increases the risk of hospitalization, stroke and death. Reactive ATP (atrial-based antitachycardia pacing) is an advanced, painless pacing therapy found exclusively on Medtronic pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices. It repeatedly sends pacing pulses to the atria during abnormally fast rhythms to restore the heart's normal rhythm, thereby slowing the progression of AF.

The retrospective analysis assessed pacemaker, ICD and CRT device data from 8,798 patients followed by the Medtronic CareLink remote monitoring system. Reactive ATP therapy was associated with a statistically significant decrease in AF events compared to a matched control group. Most notably, the Reactive ATP patient group experienced a 38 percent reduction in persistent AF events (lasting greater than seven days) (p<0.0001). This benefit was observed across patient age, sex, and device type.

"Atrial fibrillation can be a debilitating disease that imposes a significant burden upon the entire healthcare community — impacting patients, caregivers, providers and costs of care — especially as the disease progresses," said Giuseppe Boriani, M.D., Ph.D., full professor of cardiology at the University of Modena and Reggio Emilia, Italy. "These are the first real-world data on the clinical impact of Reactive ATP therapy and the first in patients with ICDs and CRT devices. These data have important implications for all device patients because of the high prevalence of AF and the correlation of disease progression to worsened patient outcomes."

This study builds upon the MINERVA trial, the first randomized, controlled study of Reactive ATP. It found that Reactive ATP therapy significantly slowed AF disease progression in patients with pacemakers with the therapy, compared to those without it. Furthermore, Reactive ATP significantly reduced AF-related hospitalizations, emergency department visits and cardioversions, resulting in payer cost savings.

For more information: www.medtronic.com

Related Content

An example of the new generation of cardiac monitoring device that is replacing Holter monitoring is the Cardea Solo wearable sensor. The FDA-cleared device automatically analyzes data when the device is turned back into the physician's office and automatically produces a draft summary report. This technology can simplify the workflow by eliminating the need for third-party involvement.

Feature | Atrial Fibrillation | September 13, 2018 | Melissa Sersland
Rapid advances in technology to monitor atrial fibrillation (AF or Afib) are enabling clinicians to access real-time
Atrial Fibrillation Patients Diagnosed With Carotid Atery Disease Face Increased Risk of Dementia

Image courtesy of Intermountain Medical Center Heart Institute

News | Atrial Fibrillation | May 24, 2018
Atrial fibrillation patients who are diagnosed with carotid artery disease face higher risks for developing dementia,...
Botulinum Toxin (botox) Injection in CABG Patients Reduces AFib After Cardiac Surgery. #HRS2018

Figure 1: At the end of 36 months, the incidence of any atrial tachyarrhythmia was 23.3 percent in the botox group, as compared to 50 percent in the placebo group

News | Atrial Fibrillation | May 18, 2018
 
Atrial fibrillation ablation using the Abbott Ensite electro mapping system. CABANA Trial Confirms Ablation Equal To or Superior to Drug Therapy. #HRS2018

Atrial fibrillation ablation using the Abbott Ensite electro mapping system.

Feature | Atrial Fibrillation | May 17, 2018
May 16, 2018 – The first results of the randomized, multicenter, long-term, international...
Link Found Between Post-Traumatic Stress, Increased Risk of AFib. #HRS2018
News | Atrial Fibrillation | May 15, 2018
May 15, 2018 — A new study is the first to report a relationship between post-traumatic stress disorder (PTSD) and ne
Marijuana Use Does Not Increase Risk of Arrhythmias, Might Reduce AFib Risk. #HRS2018
News | Atrial Fibrillation | May 15, 2018
May 15, 2018 — According to new research, smoking marijuana may not be associated with an increased risk of ventricul
First Results Reported from AVIATOR 2 Registry for AFib Patients Undergoing PCI.

Photo courtesy of the American Heart Association

News | Atrial Fibrillation | May 15, 2018
May 15, 2018 – Results of the AVIATOR 2 international registry data show a discrepancy between physician perception a
New Combined Risk Score More Effectively Predicts Stroke Risk in AFib Patients

Image courtesy of Intermountain Medical Center Heart Institute

News | Atrial Fibrillation | May 11, 2018
A new study finds that integrating two separate clinical risk score models more accurately helps clinicians assess the...
Depression Linked to Increased Atrial Fibrillation Risk
News | Atrial Fibrillation | March 27, 2018
March 27, 2018 — Depression may increase the risk for...
Overlay Init